Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Clovis Oncology Fell as Much as 13.5% Today

By Maxx Chatsko - Sep 24, 2019 at 12:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street is questioning the value and purpose of a recent deal.

What happened

Shares of Clovis Oncology ( CLVS -11.25% ) fell over 13% today after the company reported it will pay $12 million to gain control of a preclinical asset from 3B Pharmaceuticals. The deal also includes a discovery program for up to three additional disease targets using the same approach: fibroblast activation protein alpha (FAP)-targeted radionuclide therapy. 

On the one hand, the deal shows that Clovis Oncology is looking to the future. The business has struggled to position its PARP inhibitor, Rubraca, to live up to the hype in a competitive field. On the other hand, Wall Street is having a difficult time seeing the logic in the deal with 3B Pharmaceuticals. Analysts have a point.

As of 11:53 a.m. EDT, the stock had settled to a 10.5% loss.

A pink arrow crashing through the bottom axis of a chart on a chalkboard.

Image source: Getty Images.

So what

SVB Leerink analyst Andrew Berens said the deal was "ill-timed" given the company's financial headwinds, according to Barron's. In the first half of 2019, Clovis Oncology reported an operating loss of $179 million and an operating cash outflow of $196 million. Those are staggering sums of money.

While investors can't necessarily fault the business for looking to the future, acquiring the rights to a preclinical asset does raise some eyebrows. Clovis Oncology doesn't expect to file an investigational new drug (IND) application for the first drug candidate until the second half of 2020. Even if the FAP-targeted radionuclide therapy or therapies deliver on their potential, they wouldn't be on the market before 2027, based on a typical drug development timeline. Simply put, Clovis Oncology may not have that much time.

Now what

It might be tempting to label Clovis Oncology a value stock given its precipitous fall in recent years, but there's really not a whole lot for individual investors to get excited about. The business is not sustainable on its current trajectory, and it doesn't appear that Rubraca will grow into the blockbuster drug (read: at least $1 billion in annual revenue) it was once expected to become. Simply put, the worst may be yet to come for this pharma stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
$2.76 (-11.25%) $0.35
SVB Financial Group Stock Quote
SVB Financial Group
$674.57 (-5.28%) $-37.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.